At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Jeremy Thomas, MD, from the Western General Hospital, Edinburgh, United Kingdom, discusses the results of a central pathology review, including tumour type, histological grade and lymphatic invasion, of the SUPREMO trial, a randomised, global phase 3 clinical trial evaluating radiotherapy after mastectomy for patients with intermediate-risk breast cancer.
Pathology quality assurance of SUPREMO trial: Post-mastectomy radiotherapy for breast cancer
14th June 2016
Allergy & Immunology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?